Claims for Patent: 9,603,796
✉ Email this page to a colleague
Summary for Patent: 9,603,796
Title: | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Abstract: | Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). |
Inventor(s): | Lichter; Jay (San Diego, CA), Trammel; Andrew M. (Olathe, KS), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Dellamary; Luis A. (San Marcos, CA), Lebel; Carl (Malibu, CA), Harris; Jeffrey P. (La Jolla, CA) |
Assignee: | OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) |
Application Number: | 14/836,184 |
Patent Claims: |
1. A method of treating otitis externa or swimmer's ear in a patient, the method comprising administering to ear canal of the patient a composition comprising from about 10 wt % to
about 20 wt % poloxamer 407 and a therapeutically effective amount of micronized and non-microencapsulated ciprofloxacin.
2. The method of claim 1, wherein the composition comprises from about 14 wt % to about 18 wt % poloxamer 407. 3. The method of claim 1, wherein the composition comprises from about 15 wt % to about 17 wt % poloxamer 407. 4. The method of claim 1, wherein the composition comprises about 16 wt % poloxamer 407. 5. The method of claim 1, wherein the composition provides a sustained release of ciprofloxacin in the ear after a single administration, the composition having 0.02-50 mg of ciprofloxacin. 6. The method of claim 1, wherein the composition provides a sustained release of ciprofloxacin in the ear after a single administration, the composition having 1-15 mg of ciprofloxacin. 7. A method of treating otitis externa or swimmer's ear in a patient, the method comprising administering to ear canal of the patient a composition comprising from about 15 wt % to about 17 wt % of poloxamer 407 and a therapeutically effective amount of micronized and non-microencapsulate ciprofloxacin, wherein the composition provides a sustained release of ciprofloxacin in the ear after a single administration, the composition having 0.02-50 mg of ciprofloxacin. 8. The method of claim 7, wherein the composition provides a sustained release of ciprofloxacin in the ear after a single administration, the composition having 1-15 mg of ciprofloxacin. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.